Bayer's Roundup Fund: Payouts of $10,000 to $165,000, a $7.25 Billion Cap, and 200 Cases Left Outside
Published on 11/21/2026 at 13:00 | Editorial boerse-global.deBayer's long-running glyphosate litigation has a new framework, but not a finish line. A Missouri court has approved a settlement fund that will pay individual Roundup claimants anywhere from $10,000 to $165,000, according to Deutsche Welle — a range that hinges on the claimant's age, the severity of the illness and how long they were exposed to the weedkiller.
Judge Timothy Boyer signed off on the agreement, rejecting arguments that the per-person amounts were too low and calling the deal "fair, reasonable and adequate." Bayer chief executive Bill Anderson framed the approval as a milestone. The company stressed that the settlement carries no admission of liability.
Who qualifies — and who is already covered
The fund targets people who came into contact with Roundup before February 17 and have since been diagnosed with non-Hodgkin lymphoma. It also reaches those whose diagnosis arrives within 16 years of the agreement taking effect, meaning the deal is not confined to plaintiffs who have already sued.
Should investors sell immediately? Or is it worth buying Bayer?
Monsanto is on the hook for up to $7.25 billion in total, paid into the fund over as many as 21 years. That headline figure already accounts for sums disbursed to date. Annual installments are capped and taper over the life of the schedule.
The payment clock can be stopped
Court approval is not the last word. An appeal would freeze further payments until the appellate process concludes — so while the installment plan sets the financing envelope, it does not guarantee an uninterrupted flow of cash. That timing risk sits alongside the headline cap as a key variable for investors.
Nor does the fund sweep in every claim. Roughly 200 cases remain pending in US federal courts outside the settlement, leaving Bayer exposed to litigation beyond the $7.25 billion ceiling. Separate from the fund's logic, a US Supreme Court ruling in June went Bayer's way, narrowing claims that the company failed to warn of cancer risks on product packaging.
The settlement operates on a different principle: eligibility turns on Roundup exposure and a diagnosis within the defined windows, covering both existing illnesses and, under certain conditions, future ones. For a large share of the claims, that gives Bayer a defined payment perimeter — with appeals affecting when the money moves, and the excluded federal cases standing apart from it all.
Ad
Bayer Stock: New Analysis - 21 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
